Clinical Updates & Insights

All radiotherapy treatments for prostate cancer should be accompanied by image-guidance of the prostate position to rule out significant setup errors in fractional delivery.

Profiling prostate cancer tumors for microsatellite instability (MSI) status with targeted next-generation sequencing can identify patients who may respond better to PD-1/PD-L1 agents.

Men with advanced prostate cancer treated with radical prostatectomy and adjuvant radiotherapy have a lower risk of cancer-specific death and improved overall survival compared to men treated with radiotherapy plus androgen deprivation therapy.

Abbreviated breast magnetic resonance imaging is a cost-effective screening tool that should be made available to patients with an average lifetime risk of breast cancer, according to our recent review of protocols.

Surgical paradigm shifts to achieve complete cytoreduction during primary debulking surgery combined with the use of perioperative epidural anesthesia improve survival outcomes for ovarian cancer patients, our recently published research shows.

Wider negative margins do not improve local control for ductal carcinoma in situ or invasive carcinoma when they are treated with lumpectomy and radiation therapy, our recent literature review shows.

Total neoadjuvant therapy is a viable treatment strategy for patients with locally advanced rectal cancer and is associated with the potential to sidestep surgical treatment.

The “pocket-creation method” is the latest advance in endoscopic submucosal dissection, a technique for the removal of early-stage gastrointestinal cancers, further boosting its superiority over the standard approach of using endoscopic mucosal resection.

Although distraction osteogenesis is commonly employed in regular orthopedic surgery, its use in cancer patients is currently limited. But research shows that these durable reconstructions can provide superior opportunities for better long-term limb function and growth in this cohort.

Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy